What theyre saying: We believe that inhibiting new pathways on top of GLP-1 receptor agonism has the potential to achieve comparable overall reductions in body weight, but with improved quality of a weight loss, resulting in more fat loss while preserving or actually increasing muscle mass. Regenerons CSO George Yancopoulos The big picture If any of these medications (or combinations of medications) can actually enable people to lose weight while preserving muscle mass, the impact on public health could be huge but itll likely be years before they reach the market
There are people who have normal BMIs that are still obese by measured body fat standards, and we like to get people down to a normal body fat, especially the visceral fat, that stubborn belly fat that leads to prediabetes or fatty liver, says Dr
This means that people taking Ozempic may develop blood clots as a result of taking the drug
In May 2024, Nestl launched Vital Pursuit, a range of foods designed to complement GLP-1 weight loss medications
Negative feedback controls exist as part of many of our bodys processes to tightly regulate certain functions